Cerveau Technologies, Inc. Signs Research Agreement with Houston Methodist
Cerveau Technologies Inc. today announced an agreement with Houston Methodist Hospital to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
As part of the agreement, Cerveau will contract with Houston Methodist to manufacture and supply the [18F]MK-6240 needed for the initiatives in the greater Houston area as well as support research initiatives at Houston Methodist.
According to Dr. Joseph C. Masdeu, director of Houston Methodist’s Nantz National Alzheimer Center, “this new tau PET tracer could help us better understand the nature of neurodegenerative diseases, such as Alzheimer’s, and monitor the effects of existing and new therapies.”
“Cerveau welcomes this opportunity to work with Houston Methodist researchers to understand the application of MK-6240 and how it may benefit patients with this devastating disease. The collaboration with Houston Methodist will provide access to our pharmaceutical partners in support of various therapy trials as well facilitate novel research at Houston Methodist in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.
About Houston Methodist
The Houston Methodist Neurological
Institute advances the discovery of the origins, mechanisms and
treatment of neurological disease and provides comprehensive care for
patients with disorders and injuries of the brain and spinal cord. The
institute houses the practice and research activities of the departments
of neurology, neurosurgery, neuroradiology, neurophysiology, and
physical medicine and rehabilitation at Houston Methodist.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc.
is a partnership between Enigma Biomedical Group, Inc. and Sinotau
Pharmaceutical Group. Cerveau's vision is to globally develop
diagnostics and technology that positively impact patients with
neurodegenerative disorders including Alzheimer's disease.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005920/en/
Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com
